ABIOMED INC (ABMD) Forecast, Price Target & Analyst Ratings
NASDAQ:ABMD • US0036541003
381.02 USD
+0.23 (+0.06%)
At close: Dec 21, 2022
381.3 USD
+0.28 (+0.07%)
After Hours: 12/21/2022, 8:15:55 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ABIOMED INC (ABMD).
Forecast Snapshot
Consensus Price Target
$375.36
-1.49% Downside
Next Earnings Forecast
Release DateFeb 1, 2023
PeriodQ3 / 2023
EPS Estimate$1.37
Revenue Estimate306.95M
ChartMill Buy Consensus
70.00%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$375.36
Upside
-1.49%
From current price of $381.02 to mean target of $375.36, Based on 16 analyst forecasts
Low
$303.00
Median
$387.60
High
$411.60
Price Target Revisions
1 Month
19.09%
3 Months
N/A
Price Target Summary
16 analysts have analysed ABMD and the average price target is 375.36 USD. This implies a price decrease of -1.49% is expected in the next year compared to the current price of 381.02.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
70.00%
ABMD was analyzed by 16 analysts. The buy percentage consensus is at 70. So analysts seem to be have mildly positive about ABMD.
In the previous month the buy percentage consensus was at a similar level.
ABMD was analyzed by 16 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2022-11-02 | Deutsche Bank | Downgrade | Buy -> Hold |
| 2022-11-02 | Morgan Stanley | Upgrade | Underweight -> Equal-Weight |
| 2022-11-01 | William Blair | Downgrade | Outperform -> Market Perform |
| 2022-11-01 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2022-10-13 | Mizuho | Initiate | Buy |
| 2022-10-10 | Piper Sandler | Maintains | Overweight |
| 2022-07-21 | Deutsche Bank | Maintains | Buy |
| 2022-07-15 | Morgan Stanley | Maintains | Underweight |
| 2022-02-04 | SVB Leerink | Maintains | Market Perform |
| 2022-02-04 | Morgan Stanley | Maintains | Underweight |
| 2022-01-07 | Morgan Stanley | Maintains | Underweight |
| 2021-08-06 | SVB Leerink | Maintains | Market Perform |
| 2021-07-20 | SVB Leerink | Maintains | Market Perform |
| 2021-06-18 | Deutsche Bank | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateFeb 1, 2023
PeriodQ3 / 2023
EPS Estimate$1.37
Revenue Estimate306.95M
Revenue Q2Q17.53%
EPS Q2Q21.41%
Number of Analysts5
Next Earnings Revisions
Revenue (1 Month)
-3.26%
Revenue (3 Months)
N/A
EPS (1 Month)
4.13%
EPS (3 Months)
N/A
Next Earnings Summary
ABMD is expected to report earnings on 2/1/2023. The consensus EPS estimate for the next earnings is 1.37 USD and the consensus revenue estimate is 306.95M USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 840.9M 9.29% | 847.5M 0.78% | 1.032B 21.74% | 1.158B 12.24% | 1.34B 15.72% | 1.54B 14.93% | 1.684B 9.35% | 1.78B 5.70% | |
| EBITDA YoY % growth | 269.6M 12.85% | 253.7M -5.90% | 284.795M 12.26% | 296.99M 4.28% | 374.32M 26.04% | 454.29M 21.36% | 524.55M 15.47% | 571.17M 8.89% | |
| EBIT YoY % growth | 249.2M 10.85% | 229.6M -7.87% | 256.706M 11.81% | 271.28M 5.68% | 333.59M 22.97% | 408.5M 22.46% | 468.71M 14.74% | 508.63M 8.52% | |
| Operating Margin | 29.63% | 27.09% | 24.88% | 23.43% | 24.89% | 26.53% | 27.83% | 28.57% | |
| EPS YoY % growth | 4.52 -11.37% | 4.93 9.07% | 4.73 -4.06% | 4.91 3.83% | 5.69 15.86% | 7.01 23.15% | 8.21 17.16% | 9.81 19.50% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q3 / 23 | Q4 / 23 | Q1 / 24 | |
|---|---|---|---|
| EPS Q2Q % growth | 1.37 21.41% | 1.46 26.18% | 1.51 21.18% |
| Revenue Q2Q % growth | 306.95M 17.53% | 341.19M 26.44% | 356.08M 28.48% |
| EBITDA Q2Q % growth | 84.32M -1.79% | 93.364M 0.29% | 99.722M 37.23% |
| EBIT Q2Q % growth | 69.063M 6.15% | 76.76M 18.09% | 80.118M 21.30% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
14.00%
EPS Next 5 Year
15.71%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
13.62%
Revenue Next 5 Year
11.13%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
20.30%
EBIT Next 5 Year
16.96%
ABIOMED INC / ABMD Forecast FAQ
What is the price target for ABMD stock?
16 analysts have analysed ABMD and the average price target is 375.36 USD. This implies a price decrease of -1.49% is expected in the next year compared to the current price of 381.02.
When does ABIOMED INC (ABMD) report earnings?
ABIOMED INC (ABMD) will report earnings on 2023-02-01.
Can you provide the consensus estimates for ABIOMED INC next earnings?
The consensus EPS estimate for the next earnings of ABIOMED INC (ABMD) is 1.37 USD and the consensus revenue estimate is 306.95M USD.
Can you provide the analyst count for ABIOMED INC stock?
The number of analysts covering ABIOMED INC (ABMD) is 16.